All of the following criteria should be met for study entry.
Histologically confirmed adenocarcinoma prostate- grade group 3 or less (Gleason 4+3=7 or less).
Staging T2-T3a,N0M0 (MRI or DRE staging allowed).
PSA\<25.
6 months short course androgen deprivation therapy allowed, not mandated.
Maximum prostate volume 70cc.
IPSS \<12 at baseline.
WHO performance status 0 or 1.
Written informed consent.
You may not be if
Other invasive malignancy within the last two years- excluding basal cell carcinoma and squamous cell carcinoma of the skin.
Patients who, in the opinion of the Local PI, require long course (\> 6 months) ADT.
Contraindications to MRI.Including pacemaker, implanted devices, any non-MR compatible metallic implants.Severe claustrophobia.
Contraindications to gold fiducial marker implantation.Clotting disorders, very high risk of bleeding.Clinically unacceptable risk of temporarily stopping anticoagulation or antiplatelet medications.
Contraindications to prostate radiotherapy,Previous pelvic radiotherapy.Clinically significant inflammatory bowel disease.
Bilateral or single hip replacements.
Clareo Health | Prostate Radiotherapy Integrated With Simultaneous MRI (The PRISM Study)
